body > *:not(noscript) { display: none !important; } noscript { display: block !important; } .no-js-warning { display: flex !important; min-height: 100vh; align-items: center; justify-content: center; padding: 20px; background: #f8f9fa; text-align: center; } .no-js-card { max-width: 500px; padding: 30px; border-radius: 12px; background: white; box-shadow: 0 10px 30px rgba(0,0,0,0.08); font-family: Arial, sans-serif; } .no-js-card h1 { margin-bottom: 10px; }

JavaScript Required

JavaScript is required for this website to work correctly and provide a smooth user experience. Please enable JavaScript in your browser, then refresh the page.

⏳ You're moving too fast! Cooldown active — please try again in 8 minutes.

⏳ You're moving too fast! Cooldown active — please try again in 8 minutes.

Top story

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE) November 26, 2025 -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and …

Read full story

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

Drugs.com - Clinical Trial Results

Wed, 28 May 2025

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Drugs.com - Clinical Trial Results

Wed, 28 May 2025

ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM

Drugs.com - Clinical Trial Results

Wed, 30 Apr 2025

Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

Drugs.com - Clinical Trial Results

Wed, 23 Apr 2025

NIH Study Reveals How Inflammation Makes Touch Painful

Drugs.com - Clinical Trial Results

Wed, 23 Apr 2025

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Drugs.com - Clinical Trial Results

Wed, 26 Mar 2025

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Drugs.com - Clinical Trial Results

Wed, 26 Feb 2025

Camizestrant Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-Line Advanced HR-Positive Breast Cancer with an Emergent ESR1 Tumor Mutation in SERENA-6 Phase III Trial

Drugs.com - Clinical Trial Results

Wed, 26 Feb 2025

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Drugs.com - Clinical Trial Results

Wed, 26 Feb 2025